MetaCap

CytomX Therapeutics (CTMX) vs Evolus (EOLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evolus (EOLS) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 4.8% versus a loss of 47.7%. Over five years, EOLS leads with a +14.4% price change compared with -69.9% for CTMX. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $431.5 million), about 1.0 times the size, while Evolus is growing revenue faster (+11.6% vs -44.8%).

Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -22.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTMX-47.68%EOLS-4.82%
+80%+11%-58%
Nov 21, 20251 yearNov 20, 2026
CTMX-72.34%EOLS+2.19%
+188%+40%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTMX versus EOLS key metrics
MetricCTMXEOLS
Share price$2.03$6.52
Market cap$442.55M$431.55M
1-day change-0.98%-6.86%
YTD return-52.35%-1.95%
1-year return-47.68%-4.82%
5-year return-69.93%+14.39%
Forward P/E—22.68
EPS (TTM)$-0.51$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$76.20M$297.18M
Revenue growth (YoY)-44.82%+11.61%
Net income (latest FY)$-17.37M$-51.64M
Gross margin—66.33%
Operating margin-29.35%-10.99%
Net margin-22.79%-17.38%
52-week high$8.21$9.31
52-week low$1.87$3.86
Distance from 52-week high-75.27%-29.97%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+509.85%+136.20%
Average volume4.27M925.77K
Shares outstanding218.00M66.19M
Employees69365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EOLS has outperformed CTMX by 42.9 percentage points over the past year.
  • Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -22.8 cents for CytomX Therapeutics.
  • Evolus grew revenue faster in its latest fiscal year (+11.61% vs -44.82%).

About CytomX Therapeutics

CTMX stock →

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Evolus

EOLS stock →

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.

Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees

CTMX vs EOLS FAQ

Which is bigger, CytomX Therapeutics or Evolus?

CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $431.55M for Evolus (EOLS).

Which stock has performed better over the past year, CTMX or EOLS?

EOLS returned -4.82% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.

Are CytomX Therapeutics and Evolus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons